Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Datroway has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca and Daiichi Sankyo’s Enhertu recommended in EU by CHMP in HER2
- AstraZeneca’s Camizestrant recommended for approval in EU by CHMP
- AstraZeneca announces new data from portfolio, pipeline at ASCO meeting
- AstraZeneca: Buy Rating Reiterated on Late-Stage Pipeline Upside; Price Target Unchanged at 16,500 GBp
- AstraZeneca’s Earnings Call Balances Growth and Risk